These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
287 related articles for article (PubMed ID: 28148827)
21. Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma. Pellegatta S; Valletta L; Corbetta C; Patanè M; Zucca I; Riccardi Sirtori F; Bruzzone MG; Fogliatto G; Isacchi A; Pollo B; Finocchiaro G Acta Neuropathol Commun; 2015 Jan; 3():4. PubMed ID: 25849072 [TBL] [Abstract][Full Text] [Related]
22. Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma. Nagashima H; Tanaka K; Sasayama T; Irino Y; Sato N; Takeuchi Y; Kyotani K; Mukasa A; Mizukawa K; Sakata J; Yamamoto Y; Hosoda K; Itoh T; Sasaki R; Kohmura E Neuro Oncol; 2016 Nov; 18(11):1559-1568. PubMed ID: 27154922 [TBL] [Abstract][Full Text] [Related]
23. IDH1-mutated transgenic zebrafish lines: An in-vivo model for drug screening and functional analysis. Gao Y; de Wit M; Struys EA; van der Linde HCZ; Salomons GS; Lamfers MLM; Willemsen R; Sillevis Smitt PAE; French PJ PLoS One; 2018; 13(6):e0199737. PubMed ID: 29953513 [TBL] [Abstract][Full Text] [Related]
24. Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198. Molenaar RJ; Botman D; Smits MA; Hira VV; van Lith SA; Stap J; Henneman P; Khurshed M; Lenting K; Mul AN; Dimitrakopoulou D; van Drunen CM; Hoebe RA; Radivoyevitch T; Wilmink JW; Maciejewski JP; Vandertop WP; Leenders WP; Bleeker FE; van Noorden CJ Cancer Res; 2015 Nov; 75(22):4790-802. PubMed ID: 26363012 [TBL] [Abstract][Full Text] [Related]
25. Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma. Gravendeel LA; Kloosterhof NK; Bralten LB; van Marion R; Dubbink HJ; Dinjens W; Bleeker FE; Hoogenraad CC; Michiels E; Kros JM; van den Bent M; Smitt PA; French PJ Hum Mutat; 2010 Mar; 31(3):E1186-99. PubMed ID: 20077503 [TBL] [Abstract][Full Text] [Related]
26. A vaccine targeting mutant IDH1 induces antitumour immunity. Schumacher T; Bunse L; Pusch S; Sahm F; Wiestler B; Quandt J; Menn O; Osswald M; Oezen I; Ott M; Keil M; Balß J; Rauschenbach K; Grabowska AK; Vogler I; Diekmann J; Trautwein N; Eichmüller SB; Okun J; Stevanović S; Riemer AB; Sahin U; Friese MA; Beckhove P; von Deimling A; Wick W; Platten M Nature; 2014 Aug; 512(7514):324-7. PubMed ID: 25043048 [TBL] [Abstract][Full Text] [Related]
27. IDH1 mutation is associated with seizures and protoplasmic subtype in patients with low-grade gliomas. Liubinas SV; D'Abaco GM; Moffat BM; Gonzales M; Feleppa F; Nowell CJ; Gorelik A; Drummond KJ; O'Brien TJ; Kaye AH; Morokoff AP Epilepsia; 2014 Sep; 55(9):1438-43. PubMed ID: 24903073 [TBL] [Abstract][Full Text] [Related]
28. Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL. Karpel-Massler G; Ishida CT; Bianchetti E; Zhang Y; Shu C; Tsujiuchi T; Banu MA; Garcia F; Roth KA; Bruce JN; Canoll P; Siegelin MD Nat Commun; 2017 Oct; 8(1):1067. PubMed ID: 29057925 [TBL] [Abstract][Full Text] [Related]
29. IDH1 mutation diminishes aggressive phenotype in glioma stem cells. Yao Q; Cai G; Yu Q; Shen J; Gu Z; Chen J; Shi W; Shi J Int J Oncol; 2018 Jan; 52(1):270-278. PubMed ID: 29115585 [TBL] [Abstract][Full Text] [Related]
30. Low pH Facilitates Heterodimerization of Mutant Isocitrate Dehydrogenase IDH1-R132H and Promotes Production of 2-Hydroxyglutarate. Sesanto R; Kuehn JF; Barber DL; White KA Biochemistry; 2021 Jun; 60(25):1983-1994. PubMed ID: 34143606 [TBL] [Abstract][Full Text] [Related]
31. An in vivo patient-derived model of endogenous IDH1-mutant glioma. Luchman HA; Stechishin OD; Dang NH; Blough MD; Chesnelong C; Kelly JJ; Nguyen SA; Chan JA; Weljie AM; Cairncross JG; Weiss S Neuro Oncol; 2012 Feb; 14(2):184-91. PubMed ID: 22166263 [TBL] [Abstract][Full Text] [Related]
32. IDH1 Kim GH; Choi SY; Oh TI; Kan SY; Kang H; Lee S; Oh T; Ko HM; Lim JH Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31151327 [TBL] [Abstract][Full Text] [Related]
34. IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced. Zhu H; Zhang Y; Chen J; Qiu J; Huang K; Wu M; Xia C PLoS One; 2017; 12(1):e0169038. PubMed ID: 28052098 [TBL] [Abstract][Full Text] [Related]
35. IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway. Li K; Ouyang L; He M; Luo M; Cai W; Tu Y; Pi R; Liu A Oncotarget; 2017 Apr; 8(17):28865-28879. PubMed ID: 28427200 [TBL] [Abstract][Full Text] [Related]